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Perineural invasion pre-RP: Yes, 11 (6.92%); No, 108 (67.92%) and 
unknown, 40 (25.16%). Post-RP PSA: < 0.20 ng/ml: 88 (55.34%), ≥ 0.20 
ng/ml (Permanently Detectable-PSA or PD-PSA): 55 (34.59%) and 
unknown: 16 (10.06%). Initial EBRT intention: Adjuvant: 46 (28.93%), 
Salvage: 113 (71.07%). Corrected EBRT intention: Adjuvant: 23 
(14.46%), Salvage: 136 (85.53%), with 23 patients with a PD-PSA (Post-
RP PSA > 0.20 ng/ml). Androgenic deprivation: Yes 47 (29.56%), No: 
112 (70.44%). Time from BF diagnosis to EBRT referral: Mean: 16.95 
months (m), median: 5.50 m, range [0-147 m]. Pre-EBRT PSA: <1 
ng/ml: 84 (52.83%), ≥1 ng/ml: 56 (35.22%), unknown: 19 (11.95%). 
EBRT Dose: 66 Gy: 24 (19.74%), 70 Gy: 79 (59,21%), 72-74 Gy: 45 
(21,05%), interrupted: 1 (0,63%). After a median-FU of 23 m, 101 
patients (63.52%) remains free of biochemical progression, 16 patients 
(10.06%) have BP and 42 (26.42%) are lost. Perineural invasion pre-RP 
is a predictor of poor prognosis after post-RP EBRT (p = 0.012). There 
is a statistically significant benefit in BFFS when RT dose is >72 Gy (p 
= 0.048), moreover when patients with PD-PSA are analyzed (p = 
0.010). The beneficial effect of increased dose is maintained when 
pre-EBRT PSA is <1 ng/ml (p = 0.008), but not when pre-EBRT PSA is > 
1 ng/ml (p = 0.139). 
Conclusions: The majority of patients remitted to our Service for 
EBRT treatment, followed the criteria established for salvage-
treatment. Perineural invasion before RT appeared as a bad prognosis 
factor. Doses over 72 Gy were associated to longer times to BFFS, 
especially in those patients with PD-PSA. This effect was observed 
even when PSE pre.EBRT is < 1 ng/ml, but was not observed when that 
value was > 1 ng/ml. 
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Purpose/Objective: Single-institution single-arm prospective study. 
Endpoint: To assess acute toxicity (to exclude >5% of men have grade 
3 GU or any grade 3 GI). 
Materials and Methods: Since 9-2012 seven NCCN intermediate-high 
prostate cancer patients were treated with helical tomotherapy. 
Exclusion criteria: Gleason score ≥8, PSA >20, cT3b-4, IPSS≥20, history 
of acute urinary retention, difficulty following directions.CT-
simulation using Combifix™ with empty rectum and 200 ml bladder 
filled through urine catheter. CTV included prostate and seminal 
vesicles. PTV margins were 3-10 mm. Total dose to 95% PTV was 45.2 
Gy in 8 fx of 5.65 Gy on alternate days. EQD2= 78.2 Gy (a/b3) or 92.3 
Gy (a/b1.5). Rectal constraints: V43 <10%, V40 <15%, V37 <20%, V34 
<30%, V28 <40%. MVCT for on-line correction in every fraction. 
Cleansing enema prior each fraction. Bladder volume during 
irradiation was controlled through: 1) bladder filling using urine 
catheter (1st patient), or 2) measuring urine volume right after every 
fraction to provide feedback about the delay between water intake 
and treatment. All men received neoadjuvant-concomitant ADT. 
Results: Patients characteristics are cT1c-3a, Gleason score 6-7, PSA 
8-14 ng/ml.,IPSS 5-8. CTCAE acute GI toxicity: 0/7 grade 2, 2/7 grade 
1 (rectal discomfort) and 5/7 grade 0. GU figures: 1/7 grade 2 
(dysuria), 4/7 grade 1 (frequency,urgency, nocturia) and 2/7 grade 0. 
GU grade 2 toxicity was related to catheterisation manoeuvres in the 
first patient, so that dysuria resolved when bladder volume was 
controlled measuring urine. For the remaining patients the latter 
procedure was used. In total, after 56 MVCT, the mean and SD 
corrections in vertical direction were 0.58±2.4 mm (maximum 
corrections 4±1 mm).  
Conclusions: Tomotherapy-delivered extreme hypofractionated 
radiotherapy in selected prostate cancer patients shows promising 
early results. Our findings suggest that bladder catheterization should 
be avoided. 
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Purpose/Objective: The objective of this study was to evaluate the 
safety, feasibility, side-effect profile, and proof of concept of 
external beam radiotherapy (EBRT) with or without high-dose-rate 
brachytherapy (HDR-BT) for salvage of local-only failure after primary 
EBRT for prostate cancer. 
Materials and Methods: Fourteen patients (median age=68 years) with 
local-only recurrence after primary EBRT with or without BT were 
considered eligible for reirradiation. Median delivered dose in 2 Gy-
fractions at the first RT (NTD2Gy, α/β ratio=1.5 Gy) was 74 Gy (66-
98.4) using 2D- (n=4) or 3D-conformal RT (n=10). Pelvic RT and a boost 
with HDR-BT were used in 6 and 2 patients, respectively, with 
androgen deprivation therapy (ADT) used in 9 (median duration=6 
months). At relapse, all patients presented with a local failure-only as 
documented by prostate biopsies (n=11) and/or radiological imaging 
including erMRI (n=11) or PET/CT (n=12). Median time between the 
first RTand the re-irradiation was 6.1 years (range, 4.7-10.2). PSA at 
re-irradiation ranged between 4.8 and 116 ng/ml (median, 26.7 
ng/ml). Gastrointestinal (GI) and genitourinary (GU) toxicity free-
survival and biochemical relapse-free (bRFS), local relapse-free 
(LRFS), distant metastasis-free (DMFS) and cancer-specific(CSS) 
survivals were estimated with the Kaplan-Meier method  
Results: Between 2003 and 2008, a median NTD2Gy of 85.1 Gy (70-
93.4) was delivered as salvage RT to the prostate ± seminal vesicles 
(SV) with EBRT only (n=4) or EBRT + HDR-BT (n=10), adding ADT in 12 
patients (median,12 months). Median delivered dose to the whole 
prostate ± SV was 45 Gy (44-72), with a boost delivered to the local 
relapse only, using HDR-BT or IMRT in 10 and 3 patients, respectively. 
One patient was treated to the whole prostate with 72 Gy in 2.25 Gy 
per fraction using IMRT. No Grade 3 or more acute GI or GU toxicities 
were observed during RT or 6-weeks after the end of RT. At a median 
FU of 70 months (range, 48-121), the 5-yr Grade ≥ 3 GU and GI 
toxicity-free survival figures were 70±12.4% and 42.9±13.2%, 
respectively. Three patients presented with combined Grade 4 GU/GI 
toxicity consisting of rectal-prostatic and/or vesico-rectal fistula 
formation. One patient presented with rectal necrosis requiring 
colostomy. Ten and 8 patients presented with biochemical and local 
relapse, respectively. The 5-yrs bRFS, LRFS, DMFS and CSS were 
35.7±12.8%, 50.0±13.4%, 85.7±9.4% and 100%, respectively.  
Conclusions: EBRT using 3D-CRT and/or IMRT ± HDR BT as salvage 
option for patients with local recurrence after initial RT for prostate 
cancer may result in a relatively poor long-term biochemical and local 
control witha fairly high rate of severe radiation-induced side-effects. 
Alternative salvage treatment modalities should be first 
recommended, leaving reirradiation as an exceptional option only to 
be considered in very carefully selected cases. 
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Purpose/Objective: To compare acute urinary and anorectal toxicities 
in prostate cancer patients undergoing intensity modulated radiation 
therapy (IMRT) with those undergoing three dimensional conformal 
radiation therapy (3D-CRT). 
Materials and Methods: Between April 2010 and March 2012, 129 
consecutive patients who underwent definitive external beam 
radiation therapy for prostate cancer were evaluated. Patients were 
retrospectively assigned to two groups: IMRT (N = 53) and 3D-CRT (N = 
76). Acute urinary and anorectal toxicities were investigated using 
Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. 
IMRT was delivered with 74Gy/37 fractions by the 7 field step-and-
shoot technique; 3DCRT was delivered with 70Gy/35fractions by the 
static 4-6 multiple field technique. Acute toxicity was defined as the 
worst event within three months after completing radiation therapy. 
The two groups' characteristics and treatment factors were compared 
by t-test and Chi-square or Fisher’s exact test, as appropriate. The 
acute toxicity grades between the groups were compared by Mann-
Whitney U-test.  
Results: Age, National Comprehensive Cancer Network (NCCN) risk 
groups, and total doses were significantly different between the two 
groups. There were no grade 3 or higher urinary or anorectal acute 
toxicities. Although there was no significant difference in urinary 
acute toxicity, there were significant differences for rectal mucositis 
(p=0.002) and anal mucositis (p=0.011) for anorectal acute toxicity 
between the two groups, with milder toxicity in the IMRT group. 
Conclusions: Acute anorectal toxicity in prostate cancer patients 
treated with IMRT is significantly milder compared to those treated 
with 3D-CRT.  
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Purpose/Objective: Patient 1: Prostate cancer diagnosis at the age of 
71 years in March 2004, T4N0M0, Gleason 4+5, PSA 14. MRI confirmed 
involvement of vesicles, rectum and bladder. Local EBRT with photons 
in daily 2 Gy fractions to 70 Gy and 6 months of neo-adjuvant GNRH 
analogue was supplied. Follow-up for 3 years, PSA <0.4 mg/l. In April 
2007 the patient had difficulties in interpretation of reading. CT, MRI, 
whole-body acetate-PET, methionin-PET and biopsy showed a solitary 
3.5 cm metastasis in the left temporal lobe as the only sign of disease 
recurrence. Rapid complete clinical response on steroids was declared 
by the patient. Local proton boost of 12 daily fractions of 2.4 Gy (RBE 
1.1), followed by photon EBRT to the whole brain of 15 daily fractions 
of 2 Gy, in total 61.1 Gy EDQ2 (a/b 3 Gy) was given to the metastatic 
lesion. Restart with GNRH analogue for 2 years followed by 
bicalutamide so far. During the follow-up for another 5 years repeated 
PET assessments reveal a very slow resolution of the lesion. The 
patient is still healthy without any signs of prostate cancer, only 
complaining about less memory capacity.  
Patient 2. Prostate cancer diagnosis at the age of 53 years in May 
2005, T4N0M0, Gleason 4+4, PSA 158 mg/l. MRI plus spectroscopy and 
acetate-PET confirmed involvement of the left vesicle. GNRH 
analogue and bicalutamide was supplied for 6 months before 
radiotherapy (RT) and then adjuvant for 5 years. The RT applied was 
local perineal proton boost involving a major part of the vesicles of 4 
daily fractions of 5 Gy followed by IMRT to prostate and pelvic nodes 
of 25 daily fractions of 2 Gy, with dose painting up to 2.2 Gy to a 
volume of persistent SUV uptake within prostate assessment just 
before start of RT. In total 87 Gy, EDQ2 (RBE 1.1, a/b 3 Gy) to the 
prostate and 94 Gy EDQ2 to the intraprostatic boost volume was 
supplied.  
During the follow-up of more than 7 years repeated acetate-PET 
assessments reveal a notably slow decline in SUV uptake. The patient 
is still healthy without any signs of prostate cancer or GU and GI 
toxicity.  
Materials and Methods: See above. 
Results: See above. 
Conclusions: Utilizing the best available imaging in staging of very 
high risk prostate cancer allows selection of patients for highly 
advanced delivery of radiotherapy and improvement of the prognosis. 
The slow decline in SUV reveals persistent metabolic activity, which 
suggests that the radiotherapy response is permanent growth arrest 
rather than mitotic cell kill.  
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Purpose/Objective: To compare the efficacy of external beam 
radiation therapy, I-125 brachytherapy, and HIFU destruction for 
localized Stage 1-2 prostate carcinoma. 
Materials and Methods: The patients with Stage 1 and 2 prostate 
carcinoma receiving local treatments in Samara Regional Oncological 
Center from October 2007 to January 2012 were chosen for analysis. 
The treatments were local (95% isodose to CTV) external beam 3D-
conformal or intensity-modulated radiation therapy to total 74-76 Gy 
(EBRT), LDR brachytherapy with permanent seeds I-125 to total dose 
140-145 Gy (BTI125), or HIFU ablation. Prior to HIFU all patients 
underwent transurethral resection of prostate. The primary endpoint 
was time to biochemical relapse, secondary endpoint – clinical 
progression free survival. The distribution by initial parameters was 
assessed using chi-square method. The survival comparison was made 
using Kaplan-Meier’s curves and log-rank method. Cox regression was 
applied to evaluate risk factors. 
Results: Of 181 selected patients, 66 received EBRT, 61 - BTI125, 
while remaining 54 patients were treated with HIFU. Median follow-
up, initial age, prostate volume, proportion of stage 1 and PSA level 
were 24, 56, 41 months; 71, 68, 69 years, 37, 32, 36 ml; 43%, 20%, 
28% (p=0.017) and 10, 12, 12 ng/ml for EBRT, BTI125, and HIFU 
groups, respectively. Biochemical progression occurred to 25 (46%) 
patients after HIFU therapy, while in the EBRT group – to 11 (18%) and 
in BTI125 – to 16 (24%). Median time to biochemical relapse were 61.0 
(95%confidence interval (CI), 55.0-67.3), 67.3 and 34.7 months, 
p<0.0001 for EBRT, BTI125, and HIFU, respectively. In Cox 
proportional hazards model after adjustment for stage, Gleason score 
and initial PSA, EBRT (OR 0.20, CI 95%, 0.09-0.42, p<0.0001) and 
BTI125 (OR 0.31, 95% CI, 0.13-0.74, p<0.0001) remained superior to 
HIFU by means of biochemical failure. 
 
  
Conclusions: Both external beam and interstitial radiation therapy 
explicit better efficacy as compared to HIFU therapy in the treatment 
of localized Stage 1-2 prostate carcinoma. 
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Purpose/Objective: The accurate delineation of both clinical target 
volumes (CTVs) and organs at risk (OARs) is crucial in modern prostate 
radiotherapy. However, this process is time consuming and subjected 
to considerable inter-clinician variation. Auto-contouring software 
could be one way of reducing outlining times and/or reducing inter-
clinician variation. MIM is a commercially available atlas-based auto-
contouring software package and the aims of this study are to 
determine whether MIM can reduce intra-clinician variability and 
delineation times for prostate cancer. 
Materials and Methods: Five cases of locally advanced prostate 
cancer were randomly selected and seven clinicians were asked to 
delineate CTVs and OARs using a set of delineation guidelines. Total 
time required for delineation was recorded using a stop watch. A MIM 
atlas of 50 patients was prepared and stratified according to bladder 
volumes. The MIM software (version 5.1) was then used to auto-
contour the 5 original cases and clinicians were asked to edit the 
auto-contoured structures and record delineation/correction times. 
The intra-clinician variation was assessed using conformity level (CL). 
The CL and delineation times were compared with and without MIM 
using a paired t-test. 
Results: The CL pre-MIM of CTV1 varied from 0.40-0.60 (mean 0.52) 
and CTV2 between 0.50-0.61 (mean 0.52). There was no significant 
improvement in CL using MIM software for CTV1 (mean 0.54, p=0.44) 
and CTV2 (mean 0.56, p=0.22). Mean bladder CL improved from 0.68 
to 0.74 (p=0.04) with no improvement for other OARs. The delineation 
times were not significantly shorter using MIM software except the 
right hip (table 1), but varied between clinicians (figure 1).  
 
Table 1: 
Structure Delineation time pre 
MIM (mean) 
Delineation time 
post MIM (mean) 
p value (using paired t 
test) and 95% CI 
CTV1 5 min 13 sec 4 min 26 sec 0.207 (-39.73-133.59) 
CTV2 1 min 48 sec 3 min 22 sec 0.0786 (-258.71-24.76) 
Bladder 2 min 32 sec 2 min 28 sec 0.800 (-0.110 to -0.006) 
Rectum 2 min 58 sec 3 min 22 sec 0.424 (-0.082 to 0.042) 
Right hip 1 min 42 sec 1 min 04 sec 0.005 (26.7-96.1) 
